Health Condition 1: F200- Paranoid schizophrenia Health Condition 2: null- Schizophrenia
Conditions
Interventions
Intervention1: Lurasidone: 40mg hs for 3 days than 40mg BD for 8 weeks.
Intervention2: Risperidone: 3mg hs for 3 days than 3mg BD for 8 weeks
Control Intervention1: NA: NA
Sponsors
Department of Pharmacology and therapeutics
Eligibility
Inclusion criteria
Inclusion criteria: Diagnosis of Schizophrenia as per ICD-10, DCR, Patients aged between 18 to 50 years, Not on any antipsychotic for last three months, Total duration of illness less than one year, Availability of a reliable informant, Written informed consent from the patient/legally acceptable representative
Exclusion criteria
Exclusion criteria: Positive and Negative Syndrome Scale (PANSS) score 120, Presence of any other major psychiatric disorder, except nicotine dependence, Patients at risk for harm to self or others, Established treatment resistance for schizophrenia, Pregnant and lactating females, Clinical situations requiring drugs which are CYP 3A4/2D6 inhibitors or inducers, Clinical situations requiring alternative drugs or interventions eg injectable antipsychotics, ECTs, change of therapy etc., or worsening of symptoms, Patients having any major medical/surgical illness or any clinically significant abnormality in baseline investigations, Patient on any other concomitant drugs that might alter serum interleukin levels
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| positive and negative syndrome scale Schizophrenia Cognitive Rating scale UKU side effect profile Timepoint: baseline,4 and 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunological test; IL-6 estimationTimepoint: baseline and 8 weeks | — |
Countries
India
Contacts
Public ContactDr Unnati Saxena
King George Medical University, Lucknow
Outcome results
None listed